On May 23-26, the X (XXIX) National Congress of Endocrinologists with international participation "Personalized Medicine and Practical Health Care" was held in Moscow. The event brought together more than 3,000 specialists from all over the country. The Pharmasyntez Group of Companies acted as the general sponsor of the Congress.

The company presented a pipeline of antihyperglycemic agents, including Saterex, the first domestic original DPP-IV inhibitor for the treatment of type 2 diabetes mellitus. The lines of hormonal drugs "DlyaZhens" and "PlaniZhens" were also presented. The production of these drugs started in Tyumen in 2022.

A colorful stand of the Pharmasyntez Group of Companies attracted attention of a large number of specialists and industry experts.

The scientific program of the Congress included a symposium "Actual Data on Contraception and Menopausal Hormone Therapy", which was held with the support of the Pharmasyntez Group of Companies. At this event, leading specialists spoke about the myths of hormonal contraception, national criteria for contraception in 2023, the evolution of menopausal hormone therapy in patients with comorbid conditions.

"Such events allow specialists not only to learn about new drugs but also to exchange best practices in the treatment of socially significant diseases. For us, the congress has become a platform for exchanging experience and presenting to the medical community our pipeline of hormonal drugs, which is truly unique and the only one in the country," noted representatives of the Pharmasyntez Group of Companies.